Overview
CureMetrix stands at the forefront of the 2026 medical imaging market, providing FDA-cleared AI software that transforms the standard of care in mammography. Their technical architecture is built upon the proprietary Quantifi™ algorithm, designed to assist radiologists in identifying and quantifying suspicious lesions with high sensitivity and low false-positive rates. Unlike traditional CAD (Computer-Aided Detection), CureMetrix utilizes advanced deep learning to prioritize clinical worklists via cmTriage, ensuring that suspicious cases are flagged for immediate review. By 2026, the platform has matured into a comprehensive breast health ecosystem, integrating cmAssist for lesion detection and cmScore for objective density and risk assessment. The solution is typically deployed as a cloud-based or hybrid-cloud service, integrating seamlessly into existing DICOM and HL7 workflows. Its market position is defined by its ability to reduce radiologist burnout while simultaneously improving clinical outcomes through earlier detection of calcifications and masses, particularly in dense breast tissue where traditional methods often fail.